-
1
-
-
84891034178
-
Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research
-
[Epub ahead of print 1/10/2013]
-
Shane E., Burr D., et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014, [Epub ahead of print 1/10/2013]. 10.1002/jbmr.1998.
-
(2014)
J Bone Miner Res
-
-
Shane, E.1
Burr, D.2
-
2
-
-
84864742990
-
Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis
-
Sutton E., Riche D.M. Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis. Ann Pharmacother 2012, 46:1000-1009.
-
(2012)
Ann Pharmacother
, vol.46
, pp. 1000-1009
-
-
Sutton, E.1
Riche, D.M.2
-
3
-
-
84991208754
-
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis
-
Watts B., Bilezikian J.P., et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 2010, (Suppl. 3):1-37.
-
(2010)
Endocr Pract
, Issue.SUPPL. 3
, pp. 1-37
-
-
Watts, B.1
Bilezikian, J.P.2
-
5
-
-
34548413629
-
Role of RANKL inhibition in osteoporosis
-
McClung M. Role of RANKL inhibition in osteoporosis. Arthritis Res Ther 2007, 9(Suppl. 1):S3.
-
(2007)
Arthritis Res Ther
, vol.9
, Issue.SUPPL. 1
-
-
McClung, M.1
-
6
-
-
84878036757
-
Do bisphosphonates cause femoral insufficiency fractures?
-
Seraphim A., Al-Hadithy N., Mordecai S.C., Al-Nammari S. Do bisphosphonates cause femoral insufficiency fractures?. J Orthop Traumatol 2012, 13:171-177.
-
(2012)
J Orthop Traumatol
, vol.13
, pp. 171-177
-
-
Seraphim, A.1
Al-Hadithy, N.2
Mordecai, S.C.3
Al-Nammari, S.4
-
7
-
-
84155171114
-
Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw
-
Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int 2011, 22:2951-2961.
-
(2011)
Osteoporos Int
, vol.22
, pp. 2951-2961
-
-
Compston, J.1
-
8
-
-
84878953361
-
Proposed pathogenesis for atypical femoral fractures: lessons from materials research
-
Ettinger B., Burr D.B., Ritchie R.O. Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone 2013, 55:495-500.
-
(2013)
Bone
, vol.55
, pp. 495-500
-
-
Ettinger, B.1
Burr, D.B.2
Ritchie, R.O.3
-
9
-
-
84868707203
-
Incidence of atypical nontraumatic diaphyseal fractures of the femur
-
Dell R.M., Adams A.L., et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012, 27:2544-2550.
-
(2012)
J Bone Miner Res
, vol.27
, pp. 2544-2550
-
-
Dell, R.M.1
Adams, A.L.2
-
10
-
-
84885420745
-
Incidence and bone biopsy findings of atypical femoral fractures
-
Tamminen I.S., Yli-Kyyny T., et al. Incidence and bone biopsy findings of atypical femoral fractures. J Bone Miner Metab 2013, 31:585-594.
-
(2013)
J Bone Miner Metab
, vol.31
, pp. 585-594
-
-
Tamminen, I.S.1
Yli-Kyyny, T.2
-
11
-
-
84863396445
-
Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals
-
Thompson R.N., Phillips J.R., McCauley S.H., Elliott J.R., Moran C.G. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. J Bone Joint Surg (Br) 2012, 94:385-390.
-
(2012)
J Bone Joint Surg (Br)
, vol.94
, pp. 385-390
-
-
Thompson, R.N.1
Phillips, J.R.2
McCauley, S.H.3
Elliott, J.R.4
Moran, C.G.5
-
12
-
-
69049083492
-
Denosumab for prevention of fractures in postmenopausal women with osteoporosis
-
Cummings S.R., San Martin J., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756-765.
-
(2009)
N Engl J Med
, vol.361
, pp. 756-765
-
-
Cummings, S.R.1
San Martin, J.2
-
14
-
-
84893355169
-
-
[accessed 28/8/2013]
-
MHRA drug analysis print [accessed 28/8/2013]. http://www.mhra.gov.uk/home/groups/public/documents/sentineldocuments/dap_1374834463819.pdf.
-
MHRA drug analysis print
-
-
-
17
-
-
0030766092
-
Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis
-
Khan S.A., Kanis J.A., et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997, 12:1700-1707.
-
(1997)
J Bone Miner Res
, vol.12
, pp. 1700-1707
-
-
Khan, S.A.1
Kanis, J.A.2
|